Phase I trial of trastuzumab deruxtecan and neratinib in HER2-altered tumors

Dr Davis on the Investigation of Neratinib + Trastuzumab Deruxtecan in Advanced HER2+ Solid TumorsПодробнее

Phase II trial of patritumab deruxtecan in metastatic breast cancerПодробнее

Trastuzumab Deruxtecan for the Treatment of HER2+ Breast CancerПодробнее

Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancerПодробнее

Trastuzumab Deruxtecan in HER2-Low Advanced Breast Cancer | NEJMПодробнее

Optimizing Therapy in HER2+ Disease with Dr. Reshma MahtaniПодробнее

TUXEDO-1: trastuzumab deruxtecan for the treatment of HER2-positive breast cancer brain metastasesПодробнее

Trastuzumab deruxtecan doubles PFS in metastatic breast cancer with low HER2 expressionПодробнее

Neratinib/T-DM1 Doses Recommended for Phase II Trial in Breast CancerПодробнее

ELEANOR interim analysis: real-world study of adjuvant neratinib in HER2+/HR+ early breast cancerПодробнее

Trastuzumab deruxtecan in patients with breast cancer and brain metastases in DESTINY-Breast01Подробнее

Neratinib, trastuzumab + fulvestrant for HER2-mutant, HR+, metastatic breast cancerПодробнее

Trastuzumab deruxtecan: a promising agent for treating HER2-low breast cancer?Подробнее

Clinical Trials Remain Underway for Trastuzumab Deruxtecan in HER2-Positive Breast CancerПодробнее

Trastuzumab deruxtecan in metastatic HER2+ breast cancerПодробнее

Neratinib after trastuzumab-based adjuvant therapy in Her 2 positive breast cancer (ExteNET)Подробнее

DESTINY-Breast04: T-DXd for patients with HER2-low mBCПодробнее

ELEANOR: real-world study of extended adjuvant neratinib in HER2+/HR+ early breast cancerПодробнее

Trastuzumab deruxtecan shows benefit in patients with HER2 + mBCПодробнее